Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 397563, 13 pages
http://dx.doi.org/10.1155/2015/397563
Research Article

Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway

1College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea
2Korea Health Industry Development Institute (KHIDI), Cheongju, Chungbuk 363-951, Republic of Korea
3Ministry of Food and Drug Safety (MFDS), Cheongju, Chungbuk 361-709, Republic of Korea

Received 17 March 2015; Revised 4 May 2015; Accepted 24 May 2015

Academic Editor: Milica Pešić

Copyright © 2015 Dong Ju Son et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Pai, B. Soreghan, I. L. Szabo, M. Pavelka, D. Baatar, and A. S. Tarnawski, “Prostaglandin E2, transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy,” Nature Medicine, vol. 8, no. 3, pp. 289–293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Fahrer and B. Kaina, “O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer,” Carcinogenesis, vol. 34, no. 11, pp. 2435–2442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Sadanandam, C. A. Lyssiotis, K. Homicsko et al., “A colorectal cancer classification system that associates cellular phenotype and responses to therapy,” Nature Medicine, vol. 19, no. 5, pp. 619–625, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Krasinskas, “EGFR signaling in colorectal carcinoma,” Pathology Research International, vol. 2011, Article ID 932932, 6 pages, 2011. View at Publisher · View at Google Scholar
  5. J. Baselga, “Targeting the epidermal growth factor receptor: a clinical reality,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 41S–44S, 2001. View at Google Scholar · View at Scopus
  6. J. Mendelsohn, “Targeting the epidermal growth factor receptor for cancer therapy,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 1S–13S, 2002. View at Google Scholar · View at Scopus
  7. J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano, “Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives,” Annals of Oncology, vol. 16, no. 2, pp. 189–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Ciardiello and G. Tortora, “A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor,” Clinical Cancer Research, vol. 7, no. 10, pp. 2958–2970, 2001. View at Google Scholar · View at Scopus
  9. X. Chen, T. K. Yeung, and Z. Wang, “Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3,” Biochemical and Biophysical Research Communications, vol. 277, no. 3, pp. 757–763, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Normanno, C. Bianco, A. De Luca, M. R. Maiello, and D. S. Salomon, “Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment,” Endocrine-Related Cancer, vol. 10, no. 1, pp. 1–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Wei, Z. Zou, N. Becker et al., “EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance,” Cell, vol. 154, no. 6, pp. 1269–1284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Ye, Q. Gao, and M.-J. Cai, “Therapeutic targeting of EGFR in malignant gliomas,” Expert Opinion on Therapeutic Targets, vol. 14, no. 3, pp. 303–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sundvall, A. Karrila, J. Nordberg, R. Grénman, and K. Elenius, “EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma,” Expert Opinion on Emerging Drugs, vol. 15, no. 2, pp. 185–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Ciardiello and G. Tortora, “EGFR antagonists in cancer treatment,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1096–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. B. Heimberger, C. A. Learn, G. E. Archer et al., “Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa),” Clinical Cancer Research, vol. 8, no. 11, pp. 3496–3502, 2002. View at Google Scholar · View at Scopus
  16. M. Y. Khalil, J. R. Grandis, and D. M. Shin, “Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer,” Expert Review of Anticancer Therapy, vol. 3, no. 3, pp. 367–380, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-M. Huang and P. M. Harari, “Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results,” Investigational New Drugs, vol. 17, no. 3, pp. 259–269, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. B. You and E. X. Chen, “Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab,” Journal of Clinical Pharmacology, vol. 52, no. 2, pp. 125–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Mohelnikova-Duchonova, B. Melichar, and P. Soucek, “Folfox/folfiri pharmacogenetics: the call for a personalized approach in colorectal cancer therapy,” World Journal of Gastroenterology, vol. 20, pp. 10316–10330, 2014. View at Publisher · View at Google Scholar
  20. A. Mahipal, N. Kothari, and S. Gupta, “Epidermal growth factor receptor inhibitors: coming of age,” Cancer Control, vol. 21, no. 1, pp. 74–79, 2014. View at Google Scholar · View at Scopus
  21. S. Skvortsov, B. Sarg, H. Lindner et al., “Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor,” Proteomics—Clinical Applications, vol. 2, no. 6, pp. 908–914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. S. Herbst and C. J. Langer, “Epidermal growth factor receptors as a target for cancer treatment: the emerging role of imc-c225 in the treatment of lung and head and neck cancers,” Seminars in Oncology, vol. 29, no. 1, pp. 27–36, 2002. View at Google Scholar · View at Scopus
  23. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival,” The Lancet Oncology, vol. 11, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-Y. Douillard, R. Pirker, K. J. O'Byrne et al., “Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer,” Journal of Thoracic Oncology, vol. 9, no. 5, pp. 717–724, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. S. S. Sridhar, L. Seymour, and F. A. Shepherd, “Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer,” The Lancet Oncology, vol. 4, no. 7, pp. 397–406, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Boulikas and M. Vougiouka, “Cisplatin and platinum drugs at the molecular level. (Review),” Oncology Reports, vol. 10, no. 6, pp. 1663–1682, 2003. View at Google Scholar · View at Scopus
  28. J. H. Maduro, E. Pras, P. H. B. Willemse, and E. G. E. de Vries, “Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer,” Cancer Treatment Reviews, vol. 29, no. 6, pp. 471–488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Pinzani, F. Bressolle, I. J. Haug, M. Galtier, J. P. Blayac, and P. Balmes, “Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review,” Cancer Chemotherapy and Pharmacology, vol. 35, no. 1, pp. 1–9, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Mansouri-Torshizi, M. Saeidifar, A. Divsalar, and A. A. Saboury, “Interaction studies between a 1,10-phenanthroline adduct of palladium(II) dithiocarbamate anti-tumor complex and calf thymus DNA. A synthesis spectral and in-vitro study,” Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy, vol. 77, no. 1, pp. 312–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. X.-X. Chen, M.-D. Lai, Y.-L. Zhang, and Q. Huang, “Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines,” World Journal of Gastroenterology, vol. 8, no. 5, pp. 841–846, 2002. View at Google Scholar · View at Scopus
  32. Y.-D. Song, K.-F. Zhang, D. Liu et al., “Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin,” Tumor Biology, vol. 35, no. 7, pp. 7017–7024, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Son, S. J. Ha, H. S. Song et al., “Melittin inhibits vascular smooth muscle cell proliferation through induction of apoptosis via suppression of nuclear factor-kappab and akt activation and enhancement of apoptotic protein expression,” The Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 627–634, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. O. B. Jung, Y. Y. Dong, S. W. Koan et al., “Inhibition of cell growth and induction of apoptosis via inactivation of NF-κB by a sulfurcompound isolated from garlic in human colon cancer cells,” Journal of Pharmacological Sciences, vol. 104, no. 4, pp. 374–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Zhao, M. G. Wientjes, and J. L.-S. Au, “Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. A. M. Otto, R. Paddenberg, S. Schubert, and H. G. Mannherz, “Cell cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 10, pp. 603–612, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Lim, Y. Sun, S.-A. Im et al., “Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study,” World Journal of Gastroenterology, vol. 17, no. 14, pp. 1879–1888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. C. Prewett, A. T. Hooper, R. Bassi, L. M. Ellis, H. W. Waksal, and D. J. Hicklin, “Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts,” Clinical Cancer Research, vol. 8, no. 5, pp. 994–1003, 2002. View at Google Scholar · View at Scopus
  40. M. Qian, D. Qian, H. Jing, Y. Li, C. Ma, and Y. Zhou, “Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo,” Oncology Reports, vol. 32, no. 4, pp. 1681–1688, 2014. View at Publisher · View at Google Scholar
  41. R. Ashida, K. Tominaga, E. Sasaki et al., “AP-1 and colorectal cancer,” Inflammopharmacology, vol. 13, no. 1–3, pp. 113–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the systems level,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 505–516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Grossi, A. Peserico, T. Tezil, and C. Simone, “P38α mapk pathway: a key factor in colorectal cancer therapy and chemoresistance,” World Journal of Gastroenterology, vol. 20, no. 29, pp. 9744–9758, 2014. View at Publisher · View at Google Scholar
  44. Y. Ning, P. C. Manegold, Y. K. Hong et al., “Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models,” International Journal of Cancer, vol. 128, no. 9, pp. 2038–2049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Luppi, A. M. Longo, W. I. de Boer, K. F. Rabe, and P. S. Hiemstra, “Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation,” Lung Cancer, vol. 56, no. 1, pp. 25–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Kyriakakis, M. Cavallari, D. Pfaff et al., “IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation,” Journal of Leukocyte Biology, vol. 90, no. 5, pp. 929–939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Mladenova, L. Pangon, N. Currey et al., “Sulindac activates NF-kappab signaling in colon cancer cells,” Cell Communication and Signaling, vol. 11, article 73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Karin, Y. Cao, F. R. Greten, and Z.-W. Li, “NF-κB in cancer: from innocent bystander to major culprit,” Nature Reviews Cancer, vol. 2, no. 4, pp. 301–310, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. H. M. J. Roelofs, R. H. M. te Morsche, B. W. H. van Heumen, F. M. Nagengast, and W. H. M. Peters, “Over-expression of COX-2 mRNA in colorectal cancer,” BMC Gastroenterology, vol. 14, no. 1, article 1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Tanaka, M. Shimizu, H. Kohno et al., “Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet,” Life Sciences, vol. 69, no. 16, pp. 1935–1945, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. R. A. Sharma, A. Gescher, J. P. Plastaras et al., “Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells,” Carcinogenesis, vol. 22, no. 9, pp. 1557–1560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. M. E. Turini and R. N. DuBois, “Cyclooxygenase-2: a therapeutic target,” Annual Review of Medicine, vol. 53, pp. 35–57, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Alam, A. Pal, R. Kumar, P. D. Dwivedi, M. Das, and K. M. Ansari, “EGFR-mediated Akt and MAPKs signal pathways play a crucial role in patulin-induced cell proliferation in primary murine keratinocytes via modulation of Cyclin D1 and COX-2 expression,” Molecular Carcinogenesis, vol. 53, no. 12, pp. 988–998, 2013. View at Publisher · View at Google Scholar · View at Scopus